|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYP2D7 |
Gene summary for CYP2D7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYP2D7 | Gene ID | 1564 |
| Gene name | cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene) | |
| Gene Alias | CYP2D | |
| Cytomap | 22q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0001676 | UniProtAcc | A0A087X1C5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1564 | CYP2D7 | HCC1 | Human | Liver | HCC | 2.10e-06 | 1.26e+00 | 0.5336 |
| 1564 | CYP2D7 | HCC2 | Human | Liver | HCC | 2.78e-04 | 1.19e+00 | 0.5341 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
| GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
| GO:00714662 | Liver | HCC | cellular response to xenobiotic stimulus | 93/7958 | 177/18723 | 4.35e-03 | 1.89e-02 | 93 |
| GO:000167621 | Liver | HCC | long-chain fatty acid metabolic process | 60/7958 | 112/18723 | 1.17e-02 | 4.28e-02 | 60 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa01522 | Liver | HCC | Endocrine resistance | 58/4020 | 98/8465 | 1.28e-02 | 3.19e-02 | 1.78e-02 | 58 |
| hsa015221 | Liver | HCC | Endocrine resistance | 58/4020 | 98/8465 | 1.28e-02 | 3.19e-02 | 1.78e-02 | 58 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYP2D7 | SNV | Missense_Mutation | novel | c.146N>G | p.Val49Gly | p.V49G | A0A087X1C5 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-A2-A4S3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CYP2D7 | SNV | Missense_Mutation | rs781405604 | c.1060N>A | p.Asp354Asn | p.D354N | A0A087X1C5 | protein_coding | deleterious(0.01) | possibly_damaging(0.542) | TCGA-B6-A0RI-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| CYP2D7 | SNV | Missense_Mutation | rs537144704 | c.518G>A | p.Arg173His | p.R173H | A0A087X1C5 | protein_coding | deleterious(0.03) | benign(0.417) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CYP2D7 | SNV | Missense_Mutation | novel | c.1489N>T | p.Arg497Cys | p.R497C | A0A087X1C5 | protein_coding | tolerated(0.12) | possibly_damaging(0.571) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CYP2D7 | SNV | Missense_Mutation | novel | c.854N>A | p.Ser285Asn | p.S285N | A0A087X1C5 | protein_coding | tolerated(1) | benign(0) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CYP2D7 | SNV | Missense_Mutation | novel | c.571N>C | p.Cys191Arg | p.C191R | A0A087X1C5 | protein_coding | deleterious(0) | benign(0.062) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYP2D7 | SNV | Missense_Mutation | rs545151337 | c.1042N>T | p.Arg348Cys | p.R348C | A0A087X1C5 | protein_coding | deleterious(0) | benign(0.151) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CYP2D7 | SNV | Missense_Mutation | novel | c.769N>C | p.Glu257Gln | p.E257Q | A0A087X1C5 | protein_coding | deleterious(0.02) | possibly_damaging(0.53) | TCGA-4E-A92E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CYP2D7 | SNV | Missense_Mutation | novel | c.127N>A | p.Leu43Met | p.L43M | A0A087X1C5 | protein_coding | deleterious(0.02) | probably_damaging(0.957) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYP2D7 | SNV | Missense_Mutation | rs767617382 | c.1403N>A | p.Arg468His | p.R468H | A0A087X1C5 | protein_coding | deleterious(0.01) | benign(0.168) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |